1300019-46-8 Usage
1,4-Benzodiazepine core structure
The chemical has a core structure that consists of two fused benzene rings (a six-carbon ring) and a diazepine ring (a five-carbon ring with two nitrogen atoms).
5-(4-chlorophenyl) group
A chlorine atom is attached to a phenyl group (a five-carbon ring with a hydrogen atom) which is attached to the 5th position of the 1,4-benzodiazepine core structure.
2,3-dihydro group
The chemical has two hydrogen atoms attached to the 2nd and 3rd positions of the diazepine ring, indicating that the compound is a reduced form of a benzodiazepine.
7-Methoxy-2-oxo group
A methoxy group (a methyl group attached to an oxygen atom) is attached to the 7th position of the 1,4-benzodiazepine core structure, and a 2-oxo group (a carbonyl group) is present at the 2nd position of the diazepine ring.
(3S)configuration
The compound has a specific stereochemistry, with the S (sinister) configuration at the 3rd position of the diazepine ring.
Sedative and anxiolytic properties
As a benzodiazepine, the chemical is known for its effects on the central nervous system, including sedation and anxiety reduction.
Pharmaceutical use
The chemical may be used as a pharmaceutical drug due to its effects on the central nervous system, but its specific structure and configuration may result in different effects and properties compared to other benzodiazepines.
Check Digit Verification of cas no
The CAS Registry Mumber 1300019-46-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,0,0,0,1 and 9 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1300019-46:
(9*1)+(8*3)+(7*0)+(6*0)+(5*0)+(4*1)+(3*9)+(2*4)+(1*6)=78
78 % 10 = 8
So 1300019-46-8 is a valid CAS Registry Number.
1300019-46-8Relevant articles and documents
THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE
-
, (2022/02/15)
The present application is directed to a therapeutic composition, comprising two precursor compounds (monomers) that are suitable for assembly via two or more reversible covalent bonds. The monomers are polyfunctionalized molecules comprising a bioorthogo
METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
-
, (2021/08/13)
The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.
BET protein inhibitor and applications thereof
-
Paragraph 0046, (2018/04/02)
The present invention relates to a compound represented by a general formula (I) and used for inhibiting BET proteins, particularly BRD4, and uses of the compound in hyperproliferative diseases, mainly in prevention or treatment of tumor diseases, hyperplasia of prostate, inflammatory diseases, autoimmune diseases, sepsis, viral infections, vascular diseases and neurological diseases. The formula(I) is defined in the specification.
